Haleon (Haleon) Growth Rank : 0 (As of May. 11, 2024)

View and export this data going back to 2022. Start your Free Trial

What is Haleon Growth Rank?

Haleon has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Haleon Growth Rank Related Terms

Thank you for viewing the detailed overview of Haleon's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Haleon (Haleon) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Haleon PLC (NYSE:HLN) » Definitions » Growth Rank

Comparable Companies

Traded in Other Exchanges

HLNCF:USA HLN1:Mexico HLNl:UK HLN:UK H6D0:Germany

Address

The Heights, Building 5, First Floor, Surrey, Weybridge, GBR, KT13 0NY

Website

https://www.haleon.com

Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon's brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.